Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472797 · ClinicalTrials.gov registry record · Phase 3
Rebif New Formulation (RNF) Quality of Life (QOL) Study
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT00472797: Completed Phase 3 study, sponsored by EMD Serono.
NCT00472797 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 232 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00472797, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
Primary Outcome
The MSTCQ Global Side Effect domain assesses the degree of satisfaction on global side effect questions 9, 10 \& 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied). Percent change calculated as 100% \* (score at week 12 - score at baseline) / score at baseline.
Interventions
- DRUG Rebif New Formulation Non Titrated
- DRUG Rebif New Formulation Titrated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00472797 record still lists
NCT00472797 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Rebif New Formulation Non Titrated is the first listed.
NCT00472797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00472797 about?
NCT00472797 is a clinical study titled "Rebif New Formulation (RNF) Quality of Life (QOL) Study". To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
What is the current status of trial NCT00472797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2007-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00472797?
The interventions under investigation include: Rebif New Formulation Non Titrated (DRUG), Rebif New Formulation Titrated (DRUG).
Who is sponsoring clinical trial NCT00472797?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00472797's enrollment target sits among peer trials
232 1298th of 2000 higher than 701 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia